Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 51 Small Cell Lung Carcinoma 23 Breast Neoplasms 18 Sarcoma 17 Lung Neoplasms 10 Carcinoma, Hepatocellular 10 Esophageal Squamous Cell Carcinoma 9 Stomach Neoplasms 8 Neoplasms 8 Triple Negative Breast Neoplasms 7 Ovarian Neoplasms 7 Nasopharyngeal Carcinoma 7 Thyroid Neoplasms 6 Neoplasm Metastasis 6 Esophageal Neoplasms 6 Pancreatic Neoplasms 5 NSCLC 5 Colorectal Neoplasms 5 Carcinoma 5 Uterine Cervical Neoplasms 4 Pheochromocytoma 4 Endometrial Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Paraganglioma 3 Non-squamous Non-small Cell Lung Cancer 3 Glioma 3 Fallopian Tube Neoplasms 3 Cholangiocarcinoma 3

Interventions

Cyclophosphamide 25 Temozolomide 22 Vincristine 18 Irinotecan 18 Doxorubicin 13 Topotecan 10 Melphalan 10 Etoposide 10 Ifosfamide 8 Busulfan 8 cabozantinib 7 Magnetic Resonance Spectroscopy 7 Granulocyte Colony-Stimulating Factor 7 Filgrastim 6 regorafenib 5 fludarabine 5 X-Rays 5 Specimen Handling 5 Sirolimus 5 Radiotherapy 5 Gemcitabine 5 Drug Therapy 5 pegfilgrastim 4 palbociclib 4 liposomal doxorubicin 4 irinotecan sucrosofate 4 ganitumab 4 fludarabine phosphate 4 Trabectedin 4 Phantoms, Imaging 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma, Ewing × anlotinib × Clear all

NCT03416517 2019-02-15

Anlotinib and Irinotecan for Ewing Sarcoma

Peking University People's Hospital

Phase 1/2 Unknown

Neoplasm Metastasis, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡